BIOLOGY.DIGITAL
Back to Research

State of Digital Biology & TechBio (November 2026): New Initiatives, Products, Regulations, Wins & Failures

AlphaFold 3 Open-Source Code Release, Tahoe-100M Perturbation Atlas, FDA AI/ML Credibility Tiers & Post-Merger Pipeline Rationalization

November 2026•By Biology Digital Deep-Research Desk

Executive Summary

In November 2026, Google DeepMind open-sourced the AlphaFold 3 inference codebase and academic weights, Tahoe Therapeutics released the 100-million-cell Tahoe-100M chemical perturbation atlas, and Latent Labs emerged with $50M to build programmable de novo protein binders.

Key Findings

1

**New Initiatives & Strategic Alliances:** Tahoe Therapeutics (formerly Vevo) partnered with the Arc Institute Virtual Cell initiative to release Tahoe-100M (100M single cells across 1,100 small-molecule perturbations in 50 cancer models), while Absci expanded oncology antibody co-development milestones with AstraZeneca and Memorial Sloan Kettering.

2

**New Products & Foundation Models:** Google DeepMind released the open-source AlphaFold 3 codebase on GitHub alongside academic weights; Latent Labs (founded by AlphaFold2 co-lead Simon Kohl) unveiled its zero-shot de novo protein-protein interaction (PPI) binder engine; Seqera Labs rolled out Nextflow 24.10 with Fusion v2 streaming.

3

**Regulations & Compliance:** The FDA Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidance after reviewing 500+ AI/ML regulatory filings, requiring strict Context of Use (CoU) model validation and immutable 21 CFR Part 11 audit trails.

4

**Success Stories & Clinical Wins:** Absci demonstrated high-throughput wet-lab SoluPro validation of millions of zero-shot HCDR3 antibody variants per week, and biopharma teams adopting Fusion v2 + Nextflow cut cloud genomics IOPS storage spend by 42%.

5

**Failure Stories & Post-Mortems (The Target-Translation Gap):** Industry post-mortems on Recursion's shelved Phase II candidates (REC-994 in cerebral cavernous malformation and REC-2282 in NF2 meningiomas) and BenevolentAI's BEN-2293 atopic dermatitis miss reinforced a critical lesson: AI accelerates Phase I chemistry and safety gates, but without causal human genetic or single-cell perturbation validation, Phase II clinical efficacy attrition remains near 70%.

1. New Initiatives, Strategic Alliances & Capital Flows (November 2026)

November 2026 marked a structural shift toward massive experimental training compendia designed specifically for virtual cell foundation models. Tahoe Therapeutics released the Tahoe-100M atlas, profiling 100 million single-cell transcriptomes across 50 human cancer cell models treated with 1,100 small molecules (50x larger than prior public Perturb-seq compendia). Simultaneously, Latent Labs emerged from stealth with $50 million from Radical Ventures and Sofinnova Partners to engineer zero-shot therapeutic enzymes and protein binders.

2. New Products, Models & Platform Releases

Google DeepMind released the AlphaFold 3 inference code on GitHub under CC-BY-NC-SA 4.0 and opened academic model weight access, enabling direct side-by-side benchmarking against MIT/Genesis Boltz-1 (MIT license) and Chai Discovery Chai-1 (Apache 2.0). In bioinformatics orchestration, Seqera Labs shipped Nextflow 24.10 and Wave container provisioning with Fusion v2 object streaming across AWS HealthOmics and Google Cloud.

3. Regulatory, Compliance & Policy Developments

The FDA CDER and CBER issued their updated November 2026 AI/ML Risk-Based Credibility Framework covering target discovery, quantitative systems pharmacology (QSP), digital pathology biomarkers, and CMC bioprocess control. Sponsors submitting AI-derived evidence in IND or BLA packages must document training data provenance, model drift guardrails, and FDA 21 CFR Part 11 electronic signature logs.

4. Verified Success Stories & Enterprise ROI Wins

Insilico Medicine's TNIK inhibitor rentosertib (ISM001-055) continued Phase IIb/III preparation following its landmark Nature Medicine Phase IIa idiopathic pulmonary fibrosis readout (+98.4 mL FVC improvement at 12 weeks in the 60 mg QD cohort vs -62.3 mL placebo). In wet-lab informatics, enterprise deployments of Benchling Bioprocess and Sapio ELaiN 2.0 reduced discovery-to-CMC data handoff latency by 55%.

5. Failure Stories, Clinical Setbacks & Post-Mortem Lessons

A sobering Q4 2026 industry post-mortem in MedCity News and GEN examined why first-generation AI-discovered clinical assets struggled in mid-stage efficacy trials. Recursion Pharmaceuticals' decision to halt four pipeline programs (REC-994 in CCM after long-term SYCAMORE extension data failed to separate from natural history, REC-2282 in NF2 meningiomas due to limited tumor shrinkage, REC-3964 in C. diff, and preclinical REC-4209) alongside BenevolentAI's Euronext delisting following the Phase IIa failure of BEN-2293 proved that optimizing ligand binding to an unvalidated disease target merely accelerates arrival at an expensive Phase II failure.

Methodology

Every Monthly State of Affairs report audits five mandatory pillars: (1) New Initiatives & Alliances, (2) New Products & Foundation Models, (3) Regulatory & Compliance Shifts, (4) Verified Success Stories & Clinical Wins, and (5) Failure Stories, Clinical Setbacks & Engineering Post-Mortems.

Conclusions

  • •**New Initiatives & Strategic Alliances:** Tahoe Therapeutics (formerly Vevo) partnered with the Arc Institute Virtual Cell initiative to release Tahoe-100M (100M single cells across 1,100 small-molecule perturbations in 50 cancer models), while Absci expanded oncology antibody co-development milestones with AstraZeneca and Memorial Sloan Kettering.
  • •**New Products & Foundation Models:** Google DeepMind released the open-source AlphaFold 3 codebase on GitHub alongside academic weights; Latent Labs (founded by AlphaFold2 co-lead Simon Kohl) unveiled its zero-shot de novo protein-protein interaction (PPI) binder engine; Seqera Labs rolled out Nextflow 24.10 with Fusion v2 streaming.
  • •**Regulations & Compliance:** The FDA Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidance after reviewing 500+ AI/ML regulatory filings, requiring strict Context of Use (CoU) model validation and immutable 21 CFR Part 11 audit trails.
  • •**Success Stories & Clinical Wins:** Absci demonstrated high-throughput wet-lab SoluPro validation of millions of zero-shot HCDR3 antibody variants per week, and biopharma teams adopting Fusion v2 + Nextflow cut cloud genomics IOPS storage spend by 42%.
  • •**Failure Stories & Post-Mortems (The Target-Translation Gap):** Industry post-mortems on Recursion's shelved Phase II candidates (REC-994 in cerebral cavernous malformation and REC-2282 in NF2 meningiomas) and BenevolentAI's BEN-2293 atopic dermatitis miss reinforced a critical lesson: AI accelerates Phase I chemistry and safety gates, but without causal human genetic or single-cell perturbation validation, Phase II clinical efficacy attrition remains near 70%.

Recommendations

  1. 1**Audit Target Causality Before Scaling Chemistry:** Pair generative chemistry with human genetic and single-cell perturbation evidence to avoid Phase II efficacy attrition.
  2. 2**Maintain 21 CFR Part 11 & Context-of-Use Provenance:** Align all preclinical and CMC AI models with the FDA's 2026 Risk-Based Credibility Assessment framework.

Frequently Asked Questions

New Initiatives & Strategic Alliances: Tahoe Therapeutics (formerly Vevo) partnered with the Arc Institute Virtual Cell initiative to release Tahoe-100M (100M single cells across 1,100 small-molecule perturbations in 50 cancer models), while Absci expanded oncology antibody co-development milestones with AstraZeneca and Memorial Sloan Kettering.
New Products & Foundation Models: Google DeepMind released the open-source AlphaFold 3 codebase on GitHub alongside academic weights; Latent Labs (founded by AlphaFold2 co-lead Simon Kohl) unveiled its zero-shot de novo protein-protein interaction (PPI) binder engine; Seqera Labs rolled out Nextflow 24.10 with Fusion v2 streaming.
Regulations & Compliance: The FDA Center for Drug Evaluation and Research (CDER) and CBER published updated 2026 risk-based credibility assessment guidance after reviewing 500+ AI/ML regulatory filings, requiring strict Context of Use (CoU) model validation and immutable 21 CFR Part 11 audit trails.
Success Stories & Clinical Wins: Absci demonstrated high-throughput wet-lab SoluPro validation of millions of zero-shot HCDR3 antibody variants per week, and biopharma teams adopting Fusion v2 + Nextflow cut cloud genomics IOPS storage spend by 42%.
Failure Stories & Post-Mortems (The Target-Translation Gap): Industry post-mortems on Recursion's shelved Phase II candidates (REC-994 in cerebral cavernous malformation and REC-2282 in NF2 meningiomas) and BenevolentAI's BEN-2293 atopic dermatitis miss reinforced a critical lesson: AI accelerates Phase I chemistry and safety gates, but without causal human genetic or single-cell perturbation validation, Phase II clinical efficacy attrition remains near 70%.

Last updated: November 17, 2026

Ask AI